DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients

Information source: King Abdulaziz Medical City
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Hepatitis C; Renal Transplant

Intervention: Pegylated interferon alfa-2a plus ribavarin (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: King Abdulaziz Medical City

Official(s) and/or principal investigator(s):
Faisal M Sanai, MBBS, MD, Principal Investigator, Affiliation: Riyadh Military Hospital


There is a distinct lack of published literature on the effect of combination treatment of PEG-interferon and ribavirin on post-renal transplantation hepatitis C virus (HCV) patients. Small case series have been published utilizing conventional interferon and/or ribavirin and the available data is extremely preliminary in nature. A small retrospective series of patients treated with Pegylated interferon and ribavirin published recently suggests that the treatment may be safe and efficacious. Unpublished reports from a few centers within Saudi Arabia also suggest a good safety profile and reasonable efficacy from this form of combination treatment. The investigators aim to prospectively study the safety and efficacy of PEG-interferon and ribavirin combination therapy in post-renal transplant HCV-infected patients. Towards this 40 patients with histological evidence of liver disease will be recruited and the efficacy of the above medications studied. The proposed study aims to evaluate the efficacy and safety of PEG-interferon and ribavirin combination therapy in the treatment of chronic HCV in renal transplant patients in a way that will allow management of such patients in an optimized manner.

Clinical Details

Official title: Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Sustained Virologic Response

Secondary outcome: Adverse event rate and number of cases of graft rejection


Minimum age: 18 Years. Maximum age: 68 Years. Gender(s): Both.


Inclusion Criteria:

- Patients, male and female, aged 18 - 68 years

- Post renal transplant patients exceeding one year

- Anti-HCV (Abbott HCV EIA 2. 0, Abbott Diagnostic, Chicago, IL) positive > 6 months


- Detectable serum quantitative HCV-RNA (Cobas Amplicor HCV Monitor v2. 0, Roche

Molecular Systems, Pleasanton, CA) with lower limit of detection at 50 IU/mL

- Compensated liver disease with the following minimum hematologic and biochemical


- Hemoglobin > 10 g/dL

- WBC > 3000/mm3 ; granulocyte count > 1,500/mm3

- Platelet count > 75,000/mm3

- Albumin within normal limits

- TFT within normal limits

- ANA < 1: 320

- Ultrasound of the liver obtained within the preceding 6 months of study entry

- Liver biopsy prior to entry confirming a histological diagnosis consistent with HCV

necroinflammatory score (METAVIR) > 1, and fibrosis score >/= 2. Exclusion Criteria:

- Previous treatment with interferon and / or Ribavirin - based therapy for chronic

hepatitis C

- Co-infection with HBV or HIV

- Chronic alcohol abuse (daily consumption > 20 g/day)

- Autoimmune or metabolic liver disease liver disease

- Active drug-induced hepatitis or HAV

- Decompensated liver disease (Child-Pugh classification B or C) including a past

history of decompensation

- Variceal bleeding

- Evidence of severe retinopathy (e. g. CMV retinitis, macula degeneration) or

clinically relevant ophthalmological disorder due to diabetes mellitis or hypertension

- Neoplastic disease

- Patients with a value of alpha-fetoprotein >100 ng/mL will be excluded from the study

until imaging studies confirm the absence of HCC. Presence of HCC, as determined by other means will also exclude the patient from histological sampling.

- Patients with documented or presumed coronary artery disease or cerebrovascular

disease should not be enrolled if, in the judgment of the investigator, an acute decrease in hemoglobin by up to 4 g/dL (40 g/L) (as may be seen with ribavirin therapy) would not be well-tolerated

- History of severe psychiatric disease, especially depression. Severe psychiatric

disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease

- Evidence of drug abuse (including excessive alcohol consumption) within one year of

study entry

- Current pregnancy, ongoing breast feeding or unwilling to have contraception

- Bleeding or clotting diatheses

- Recent history of renal allograft rejection (< 6 months)

- Inability or unwillingness to provide informed consent or abide by the requirements

of the study.

- History or other evidence of severe illness or any other conditions which would make

the patient, in the opinion of the investigator, unsuitable for the study.

- History of organ transplantation, other than kidney, with an existing functional


- Patients requiring dialysis or in whom dialysis is impending.

Locations and Contacts

King Faisal Specialist Hospital & Research Centre, Riyadh 11159, Saudi Arabia

Riyadh Military Hospital, Riyadh 11159, Saudi Arabia

Additional Information

Starting date: January 2009
Last updated: September 13, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017